What does federal research and development mean?

Represents federal-level tax credits or specific R&D-related tax incentives claimed by the company. This metric highlights the extent to which government policy subsidizes the company's innovation pipeline.

Citius Oncology, Inc. CTOR Federal Research And Development

Federal Research And Development at other companies

Curtiss-WrightCW

$52.53M-13.6%

Lightpath TechnologiesLPTH

-$56.38K-49.5%

ADTRAN Holdings, Inc.ADTN

$2.95M+28.3%

Syntec Optics Holdings, Inc.OPTX

$740.87K+8.2%

Motorcar Parts of AmericaMPAA

$64K—

Opus GeneticsIRD

$0—

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept ctor:FederalResearchAndDevelopment.

The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s federal research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s federal research and development?: Citius Oncology, Inc. (CTOR) reported federal research and development of $395.25K in Q3 2025.
What does federal research and development mean?: Represents federal-level tax credits or specific R&D-related tax incentives claimed by the company. This metric highlights the extent to which government policy subsidizes the company's innovation pipeline.